Uzi Sofer

CEO, Alpha Tau Medical

Search every verified Uzi Sofer interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Uzi Sofer, founder, CEO, and chairman of Alpha Tau Medical, discussed the company's decision to begin trading on the Tel Aviv Stock Exchange in August 2026, in addition to its existing Nasdaq listing. He stated that the timing was driven by significant interest from Israeli institutional investors and noted that the company had recently completed patient enrollment for its third pivotal trial in the United States. Sofer said the company is in a follow-up phase with patients treated in May, with final results expected to be submitted to the FDA by the end of the year. Sofer also described the company's technology, which uses alpha radiation delivered directly into tumors, and said it has received regulatory approvals in Israel and Japan while progressing toward U.S. approval. He stated that the potential market is large, as the tool can treat any solid tumor, and that the company is preparing manufacturing capacity to meet anticipated demand.